Clinical Trial

A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Solid Tumors

Study acronym: GK01IIT-TZ03
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a open-label, single-arm clinical trial designed to evaluate the safety, pharmacokinetic profile, and preliminary efficacy of the GK01 cell injection in combination with a PD-1 monoclonal antibody for the treatment of advanced solid tumors.
Trial Details
NCT Number NCT07407985
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Collaborators: Beijing Geekgene Technology Co., LTD
Conditions Solid Tumors
Enrollment 15 participants
Start Date 2025-12-04
Primary Completion 2027-12-03 (estimated)
Study Completion 2028-12-02 (estimated)
Updated on ClinicalTrials.gov 2026-02-12